Table 1.
Baseline characteristics
| p16 unmethylated (n=35) | p16 methylated (n=14) | p-valuea) | |
|---|---|---|---|
| Sex | |||
| Male | 21 (60.0) | 9 (64.3) | 1.00 |
| Female | 14 (40.0) | 5 (35.7) | |
| Median age (range, yr) | 59 (39-69) | 59 (27-77) | 0.94 |
| ECOG PS | |||
| 0 | 23 (65.7) | 9 (64.3) | 0.92 |
| 1 | 12 (34.3) | 5 (35.7) | |
| Histology | |||
| WD/MD | 31 (88.6) | 12 (85.7) | 0.78 |
| PD/Mucinous | 4 (11.4) | 2 (14.3) | |
| Tumor location | |||
| Proximal | 8 (22.9) | 4 (28.6) | 0.72 |
| Distal | 27 (77.1) | 10 (71.4) | |
| Disease status | |||
| Metastatic | 27 (77.1) | 5 (35.7) | 0.006 |
| Recurrent | 5 (22.9) | 9 (64.3) | |
| Metastatic site | |||
| Liver | 24 (68.6) | 7 (50) | 0.54 |
| Lung | 2 (5.7) | 1 (7.1) | |
| Peritoneum | 3 (8.6) | 1 (7.1) | |
| Others | 6 (17.1) | 5 (35.7) | |
| Prior chemotherapy | |||
| 0 | 17 (48.6) | 5 (35.7) | 0.41 |
| 1 | 18 (51.4) | 9 (64.3) | |
| KRAS | |||
| Wild type | 32 (91.4) | 8 (57.1) | 0.01 |
| Mutant | 3 (8.6) | 6 (42.9) | |
| CIMP | |||
| CIMP negative | 28 (80.0) | 4 (28.6) | 0.002 |
| CIMP positive | 7 (20.0) | 10 (71.4) | |
Values are presented as number (%). ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CIMP, CpG island methylator phenotype.
a)
Chi-square test.